HANSA BIOPHARMA AB SK 1HANSA BIOPHARMA AB SK 1HANSA BIOPHARMA AB SK 1

HANSA BIOPHARMA AB SK 1

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪130.19 M‬EUR
−1.392EUR
‪−74.38 M‬EUR
‪11.99 M‬EUR
‪45.82 M‬
Beta (1Y)
−0.77

About HANSA BIOPHARMA AB

CEO
Søren Tulstrup
Headquarters
Lund
Employees (FY)
168
Founded
2007
ISIN
SE0002148817
FIGI
BBG00F6HRCP9
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange HANSA BIOPHARMA AB SK 1 stocks are traded under the ticker 24H.
HANSA BIOPHARMA AB SK 1 is going to release the next earnings report on Jul 18, 2024. Keep track of upcoming events with our Earnings Calendar.
24H earnings for the last quarter are −0.36 EUR per share, whereas the estimation was −0.30 EUR resulting in a −19.94% surprise. The estimated earnings for the next quarter are −0.24 EUR per share. See more details about HANSA BIOPHARMA AB SK 1 earnings.
HANSA BIOPHARMA AB SK 1 revenue for the last quarter amounts to ‪4.85 M‬ EUR despite the estimated figure of ‪4.68 M‬ EUR. In the next quarter revenue is expected to reach ‪4.61 M‬ EUR.
Yes, you can track HANSA BIOPHARMA AB SK 1 financials in yearly and quarterly reports right on TradingView.
24H net income for the last quarter is ‪−18.92 M‬ EUR, while the quarter before that showed ‪−11.13 M‬ EUR of net income which accounts for −70.00% change. Track more HANSA BIOPHARMA AB SK 1 financial stats to get the full picture.
No, 24H doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 24H shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANSA BIOPHARMA AB SK 1 stock right from TradingView charts — choose your broker and connect to your account.
24H reached its all-time high on Oct 9, 2018 with the price of 32.880 EUR, and its all-time low was 1.714 EUR and was reached on Oct 16, 2023. View more price dynamics on 24H chart.
See other stocks reaching their highest and lowest prices.
As of May 9, 2024, the company has 168.00 employees. See our rating of the largest employees — is HANSA BIOPHARMA AB SK 1 on this list?
We've gathered analysts' opinions on HANSA BIOPHARMA AB SK 1 future price: according to them, 24H price has a max estimate of 14.93 EUR and a min estimate of 5.80 EUR. Watch 24H chart and read a more detailed HANSA BIOPHARMA AB SK 1 stock forecast: see what analysts think of HANSA BIOPHARMA AB SK 1 and suggest that you do with its stocks.